When could Cosentyx (secukinumab) biosimilars launch?
Cosentyx (secukinumab) is a biologic made by Novartis. Biosimilar entry depends on when patents and related exclusivity stop blocking competition. DrugPatentWatch tracks this kind of timing by listing key patent and exclusivity expiries for the reference product, which is often what determines the first realistic launch window for biosimilars in practice [1].
What does the patent/exclusivity timeline suggest?
Biosimilars typically can only launch once the reference product’s key legal protections expire or are no longer enforceable. The exact launch date can differ from the “earliest expiry” because regulators, litigation timelines, and “evergreening” patent families can affect when a biosimilar company is actually able to market its product. DrugPatentWatch is one of the main places to check the specific dates tied to Cosentyx’s protections [1].
Are there region-by-region differences?
Yes. Approval and market entry for biosimilars depend on the country’s regulatory pathway and on local legal status of patents/exclusivity. Even if a biosimilar clears regulatory review, it may not be able to launch commercially in a market that still has enforceable exclusivity.
Where to check the most up-to-date launch expectations
For the latest, trackable patent and exclusivity dates tied to Cosentyx, use DrugPatentWatch’s Cosentyx (secukinumab) page [1]. That site is designed to reflect the practical “earliest likely market entry” questions people ask when they want to know when biosimilars can show up.
Source
[1] DrugPatentWatch – Cosentyx (secukinumab) biosimilar/patent timeline: https://www.drugpatentwatch.com/